Yes, no-one knows if they've been approached although my past experience with Novartis is they wait until the last 6 months before a trial result is due to make a licensing deal.
However with the patents off Eyelea and Lucentis and a number of generics available, if the trials are successful, then Opthea should be holding all the important cards.
Ann: Trading Halt, page-30
-
- There are more pages in this discussion • 96 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.010(2.27%) |
Mkt cap ! $553.9M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 45.5¢ | 43.5¢ | $417.7K | 934.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9400 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 26000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |